Literature DB >> 32035242

Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer.

Shiva Najjary1, Reza Mohammadzadeh2, Ahad Mokhtarzadeh3, Ali Mohammadi4, Amir Baghbanzadeh Kojabad3, Behzad Baradaran5.   

Abstract

Breast cancer (BC) is the most common cancer among women that is responsible for the most of the cancer-related death in worldwide. Drug resistance is remaining as a significant clinical obstacle to treat BC patients effectively. Therefore, to help overcome this problem, it is necessary to understand the mechanisms of drug resistance. microRNAs classify as highly conserved non-coding RNAs (~22 nucleotides) and interact with mRNAs-coding genes for direct post-transcriptional repression. It has been reported that miR-21 is overexpressed and also acts as oncomiR in many human malignancies by targeting of several tumor suppressor genes-associated with apoptosis, proliferation and metastasis. Specifically, it has been reported that miR-21 is responsible for the drug resistance and its overexpression is related to the development of Multi Drug Resistance (MDR) in breast cancer. In this review, we discussed about the role of miR-21 on the drug resistance of breast cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Drug resistance; miR-21; microRNA

Year:  2020        PMID: 32035242     DOI: 10.1016/j.gene.2020.144453

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

Review 1.  Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer.

Authors:  Abirami Arunachalam; Dinesh Kumar Lakshmanan; Guna Ravichandran; Soumi Paul; Sivakumar Manickam; Palanirajan Vijayaraj Kumar; Sivasudha Thilagar
Journal:  Med Oncol       Date:  2021-09-04       Impact factor: 3.064

Review 2.  Exosome-Mediated Response to Cancer Therapy: Modulation of Epigenetic Machinery.

Authors:  Mohammad Imran Khan; Reem K M E Alsayed; Hani Choudhry; Aamir Ahmad
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 3.  Revisiting the miR-200 Family: A Clan of Five Siblings with Essential Roles in Development and Disease.

Authors:  Vignesh Sundararajan; Ulrike C Burk; Karolina Bajdak-Rusinek
Journal:  Biomolecules       Date:  2022-06-03

4.  miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Mariarosaria Incoronato
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

Review 5.  Preclinical Imaging Evaluation of miRNAs' Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review.

Authors:  Francesca Maria Orlandella; Luigi Auletta; Adelaide Greco; Antonella Zannetti; Giuliana Salvatore
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

6.  Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy.

Authors:  Lei-Ming Guo; Gao-Feng Ding; Wen-Cai Xu; Hong Ge; Yue Jiang; Yu-Fei Lu
Journal:  Oxid Med Cell Longev       Date:  2022-03-07       Impact factor: 6.543

7.  A Systematic Way to Infer the Regulation Relations of miRNAs on Target Genes and Critical miRNAs in Cancers.

Authors:  Peng Xu; Qian Wu; Jian Yu; Yongsheng Rao; Zheng Kou; Gang Fang; Xiaolong Shi; Wenbin Liu; Henry Han
Journal:  Front Genet       Date:  2020-03-31       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.